Introduction. In an earlier study, our group reported that circulating leucocytes in hypertensive (HT) patients show a significant increase in oxidative stress compared to the control group, and this normalised after two months of treatment with eprosartan.
Introduction
Recently, growing attention is being given to the cell damage induced by free radicals (ROS) under circulatory flow conditions. Various kinds of stress can cause an increase in oxidants, and although the stress agents operate by way of different mechanisms, all lead to a greater production of ROS that, in turn, can oxidise various vital cell components. ROS induce oxidative stress when the organism does not have sufficient ability to eliminate them.
In arterial hypertension, as we described in a previous study, 1 leucocytes have greater mitochondrial membrane potential and there is also greater spontaneous production of hydrogen peroxide by lymphocytes. These results concur, in general, with those described by other authors, 2 and suggest that hypertensive (HT) patients are in a state of oxidative stress that could be due to an overproduction of oxidative products or to the fact that the anti-oxidant defence system has been overloaded.
It is well established that the cellular anti-oxidant system can be enzymatic or non-enzymatic. The enzymatic system acts through diverse compounds and processes with the aim of eliminating excess oxidant, just as superoxide dismutase (SOD) and catalase (CAT) function. SOD is the first enzyme of the anti-oxidant process and it catalyses the reaction that converts the anion superoxide into oxygen and hydrogen peroxide which, in turn, becomes oxygen and water through the action of CAT. This mechanism means that both enzymes constitute an important defence mechanism against oxidative stress. 3 Various types of SODs have been described, 4 and all provide an essential defence system for live cells. 5 CAT uses hydrogen peroxide as a source of electrons and is found in almost all eucaryotic cells, located in peroxisomes. 6 It is considered the main regulator of hydrogen peroxide metabolism. Hydrogen peroxide at high concentrations is a toxic agent to the cell, while at low concentrations it seems to modulate some physiological processes such as cell proliferation, apoptosis, carbohydrate metabolism, and platelet activation. 7 Superoxide dismutase and catalase anti-oxidant activity in leucocyte lysates from hypertensive patients: effects of eprosartan treatment In a previous study by our group, we reported for the first time in the literature consulted that eprosartan normalises to a great extent the oxidative stress alterations of leucocytes in HT patients. 1 This seems to suggest that these cells may be a drug target, although the most likely mechanism of action is not clear. Since leucocytes have angiotensin II type 1 receptor in their membrane 8 and eprosartan blocks these receptors, it can be speculated that eprosartan acts along this pathway, preventing leucocyte activation/oxidative stress. However, there may be other mechanisms involved, such as changes in the anti-oxidant enzyme capacity in the leucocytes of HT patients, which could be normalised by the action of eprosartan. This hypothesis could be tested by measuring the activity of both enzymes in peripheral leucocytes under baseline conditions (immediately before the initiation of treatment with eprosartan) and two months after initiation of the medication. Therefore, the objective of the present study was to evaluate if the existence of a state of oxidative stress in the leucocytes of HT patients, described previously by our group, is accompanied by changes in the anti-oxidative capacity of these cells. Additionally, this study assessed whether the normalising effect of eprosartan on oxidative stress can be attributed to its action on the cellular anti-oxidant enzyme defence system.
Patients and methods

Patients
In this prospective pilot study, 21 consecutive HT patients were studied (seven women and 14 men, age 51.5±4.1 years, body mass index 26.8± 3.2 kg/m 2 ). The patients included were HT type 1-2 according to WHO classification (systolic blood pressure 140-189 mmHg or diastolic 90-109 mmHg), without renal, hepatic, or cardiac organ damage, and they were recruited after a two-week washout period (baseline conditions). There was one patient with type II diabetes and five with hypercholesterolaemia. All of them were controlled through adequate medication. Two of the patients smoked more than 10 cigarettes/day and two were drinkers of more than 30 g alcohol/day. None of the patients presented a personal clinical history of previous thrombosis, although four of them related a family history of such episodes. During the follow-up period, the recruited patients maintained their lifestyle and habitual diet.
The control group consisted of a comparable normotensive group, composed of nine women and 16 men (age 53.9±4.2 years, body mass index 25.9±2.5 kg/m 2 ), without personal or family history of cardiovascular events and with the same percentage of added risk factors (diabetes, hypercholesterolaemia, smoking and alcohol intake) as the patient group.
The possible effect of eprosartan on the antioxidant enzyme system was evaluated studying the patients at baseline (immediately before initiating treatment) and two months after the initiation of it (600 mg/day in one dose). The recruitment of cases and follow-up were carried out in accordance with the principles of the Declaration of Helsinki and were approved by the Ethics Committee of the Clinic University Hospital of Valencia.
Methods
Leucocyte preparation
Venous blood was obtained from patients and healthy volunteers after 12 hours of fasting and K3-ethylene diamine tetraacetic acid (EDTA) was added to prevent coagulation. Leucocytes were isolated by the Histopaque 1077 gravity technique. Blood (3 ml) was layered over 8 ml of Histopaque 1077 (Sigma-Aldrich, St. Louis, MO, USA) in a 15-ml plastic tube. After 45-60 minutes of gravity sedimentation at room temperature, the leucocyte-rich plasma (upper layer) was removed and the agglutinated erythrocytes were discarded. White blood cells were diluted 1.0:0.5 v/v in RPMI 1640 culture medium (Gibco, Paisley, UK) supplemented with 10% foetal bovine serum (Gibco, Brooklyn, NY, USA), penicillin (100 U/ml; Gibco, Brooklyn), streptomycin (100 μg/ml; Gibco, Brooklyn) and 1× glutamine (Sigma-Aldrich), and were incubated for 30 minutes at 37°C. The diluted leucocytes were counted in a Sysmex XE-2100 autoanalyser (Makinohara Kaigandori, Kobe, Japan) and were adjusted to a concentration of 500,000 cells/ml with RPMI.
Enzyme assays
The activities of enzymes involved in ROS metabolism, SOD and CAT, were determined in cell lysates. No separation techniques (such as flow cytometry) were used to separate the different kinds of leucocytes. Cell lysates were prepared as follows: the cells were resuspended with phosphate-buffered saline (pH 7.4), and sonicated for 10 minutes until the solution was clear. SOD and CAT activities were measured using the Bioxytech SOD-525 and Bioxytech Catalase-520 kits (OxisResearch, Foster City, CA, USA), respectively, according to the manufacturer's instructions. Protein concentrations were determined by Bradford's method, 9 which is especially recommended for determining the protein content of cell fractions. Quantification of total SOD activity SOD activity was measured using the Bioxytech SOD-525 kit (OxisResearch; Catalogue Number: 21010) according to the manufacturer's instructions. The method is based on the SOD-mediated increase in the rate of autoxidation of 5, 6, 6a, 11b-tetrahydro-3, 9, 10-trihydroxybenzo[c]fluorine (R1 reagent) in aqueous alkaline solution to yield a chromophore with maximum absorbance at 525 nm. 10 The kinetic measurement of the 525 nm absorbance change is performed after the addition of R1. One SOD-525 activity unit is defined as the activity that doubles the autoxidation rate of the control blank.
Briefly, the experimental procedure was as follows: 40 μl of samples and blanks were incubated in 900 μl of SOD-525 buffer at 37°C, then 30 μl of the R2 reagent were added and incubated at 37°C for 1 minute before addition of 30 μl of the R1 reagent. A 525 nm was measured every 3 seconds for 2 minutes.
Quantification of CAT activity CAT activity was measured using the Bioxytech Catalase-520 kit (OxisResearch; Catalogue Number: 21042) according to the manufacturer's instructions. The Catalase-520 assay is a two-step procedure. The rate of hydrogen peroxide (H 2 O 2 ) decomposition to water and molecular oxygen is proportional to the concentration of CAT. Therefore, the sample containing CAT is incubated in the presence of a known concentration of H 2 O 2 . After having been incubated for exactly 1 minute, the reaction is quenched with sodium azide. The amount of H 2 O 2 remaining in the reaction mixture is then determined by the oxidative coupling reaction of 4-aminophenazone (4-aminoantipyrene, AAP) and 3,5-dichloro-2-hydroxybenzenesulphonic acid (DHBS) in the presence of H 2 O 2 and catalysed by horseradish peroxidase (HRP). The resulting quinoneimine dye is measured at 520 nm. 11 Briefly, the experimental procedure was as follows: cell lysates (30 µl) and various amounts of the standard CAT (for standard curve generation) were incubated with 500 µl of 10 mM H 2 O 2 for 1 minute at 37°C and the reaction was stopped by addition of 500 µl of sodium azide solution. Aliquots (20 µl) were incubated with the HRP/ chromogen reagent for 10 minutes. Optical densities were read at 520 nm absorbance.
SOD and CAT enzyme activities, obtained in U/ml, are expressed in U/mg of protein, for which the concentration of proteins in leucocyte lysates was determined using the Bradford method. 9 In the peripheral blood samples anticoagulated with EDTA, the number of leucocytes and the percentage of neutrophils were calculated in a Sysmex XE-2100 autoanalyser, as markers of an inflammatory state, even if slight, can be present with hypertension. 12, 13 The routine biochemical parameters were determined with an OLYMPUS 5400 autoanalyser (Sunto-gun, Shizuoka-ken, Japan) and the haemostatics using an ACL 9000 (Instrument Laboratory, Lexington, MA, USA). The haemostatic parameters included evaluation of the plasma fibrinogen concentration, which is currently considered to be an independent risk factor for cardiovascular disease. 14 
Results
Blood pressure changes and safety considerations
The most relevant clinical results can be found in table 1. It can be seen that, as expected, the patient group at baseline presented statistically None of the patients included in the study had to discontinue due to undesirable side-effects attributable to eprosartan.
Routine analytical results
The results corresponding to the clinical chemistry parameters are summarised in In relation to the routine haematological parameters, no significant differences were observed among the three groups regarding their number of neutrophils, lymphocytes, monocytes or leucocytes (results not shown).
In the untreated HT patients, the monocytes to leucocytes ratio tended to be greater than that of the control group (0.076±0.060 vs. 0.068±0.010). Nevertheless, this difference was not statistically significant.
Some significant haematological and haemostatic parameters, including the haematocrit value and the haemoglobin value, were slightly greater in the HT patient group than in the normotensive controls (46.1±2.9% and 15.4±1.2 g/dl vs. 43.6±3.9% and 13.9±1.8 g/dl, respectively, p<0.05). After two months of treatment with eprosartan, both parameters tended to decrease, with end-values of 45.2±2.9% and 15.1±1.2 g/dl, respectively. There were no significant differences observed in platelet count or in plasma fibrinogen concentration among the treated patients, untreated patients or the control group (results not shown).
In general, the results of this study suggest that routine clinical chemistry, and haematological and haemostatic parameters do not undergo significant changes after treatment with eprosartan, with the exception of the beneficial changes observed in the plasma levels of total cholesterol and low-density lipoprotein cholesterol.
Enzymatic activities from leucocytes * Table 3 shows the results obtained in relation to the anti-oxidant activity in leucocytes. These data suggest that at baseline, the HT patients present greater SOD and CAT enzyme activities than the control group (0.16±0.04 U/mg and 7.23±1.62 U/mg vs. 0.13±0.04 U/mg and 5.36±1.32 U/mg, p<0.05 and p<0.001, respectively). These tended to decrease after two months of treatment with eprosartan and end-values were similar to those in the control group (0.14±0.05 U/mg SOD activity and 6.45±1.38 U/mg CAT activity). It can be seen in figure 1 that at baseline, 18 out of 21 patients studied showed SOD activity which was greater than the mean value of the control group. After two months of treatment with eprosartan, this number dropped to 13 cases. With reference to the CAT activity, figure 2 shows that all patients at baseline presented enzyme activity that was greater than the mean value of the control group, and that after two months of treatment, only 15 of the patients fulfilled this condition.
Discussion
At the dose tested, eprosartan proved to be an effective and safe drug in the treatment of HT patients, in accordance with what has been published by other authors. [15] [16] [17] During the observation period studied, there were no relevant changes observed in the clinical chemistry, haematological or haemostatic parameters which could have been attributed to treatment with eprosartan, except that eprosartan appeared to decrease the plasma concentrations of total cholesterol and low-density lipoprotein cholesterol in the patients studied.
The existence of cellular oxidative stress in HT is well established [18] [19] [20] [21] [22] [23] and constitutes one of the 'nonclassic' risk factors of cardiovascular disease. 24 It has been shown that angiotensin II works as a stimulant in the activation of polymorphonuclear leucocytes, principally neutrophils, 8 by which drugs capable of inhibiting the membrane highaffinity angiotensin II type 1 receptor can consequently reduce oxidative stress. From this point of view, it was expected that our untreated HT patients would exhibit greater oxidative stress than the normotensive group and that the treatment with eprosartan would reduce this stress, just as we described in a previous study. 1 One of the possible mechanisms by which eprosartan exerts an anti-oxidative stress effect may be that exercised in the blocking of angiotensin II type 1 receptors present on the leucocyte surface. 8, 25 However, eprosartan may also act on cellular oxidative stress by way of its effect on the mobilisation of intracellular cytoplasmic free calcium, which, while altered in untreated HT patients, is normalised through treatment with eprosartan. 26 The normalisation of intracellular calcium mobilisation is accompanied by a reduction in cell activation and, in theory, should be accompanied by a reduction in oxidative stress.
In addition to the non-enzymatic mechanisms, by which eprosartan acts against oxidative stress, enzymatic mechanisms may also be involved such as the increase in anti-oxidant enzyme activity. The results of this study suggest that, paradoxically, untreated HT patients present greater anti-oxidant activity in leucocytes than the normotensive group and that eprosartan normalises this activity, approximating the values of the control group.
The results obtained in this study allow us to establish that leucocytes in HT patients at baseline are characterised by greater SOD and CAT Individual values of SOD activity in controls, HT patients at baseline and after two months of eprosartan treatment. Group
CAT activity U/mg
Figure 2
Individual values of CAT activity in controls, HT patients at baseline and after two months of eprosartan treatment. Table 3 Mean value, standard deviation and statistical significance of leucocyte anti-oxidant enzymatic activity in HT patients at baseline, after two months of treatment with eprosartan and the control group. anti-oxidant activity than the normotensive group. Other authors 2, 24, 27, 28 have also reported, as in our group, greater oxidative stress in the leucocytes of uncontrolled HT patients. However, Kumar and Das 2 observed a lower SOD antioxidant activity in such patients at baseline, which is contrary to what was observed in our study. Nevertheless, it must be noted that, since oxidative stress induces adaptations in the expression of protective anti-oxidant enzymes in a wide variety of tissues, 29 the oxidative stress in leucocytes induced by hypertension could provoke, as observed in our results, an increase and not a decrease in SOD and CAT activities. Treatment with eprosartan leads to a reduction in these activities, parallel to the normalisation of blood pressure values. Currently, the idea of a 'vicious circle' between hypertension and ROS is widely accepted, according to which the increase of ROS does not only play a critical role in the initiation of hypertension, but also, in turn, can be generated by hypertension itself, thus perpetuating the vicious circle. 18, 30 According to this mechanism, the increase in oxidative stress observed in untreated HT patients should be accompanied by an increase in SOD and CAT activities that helps to reverse the situation as a result of its antioxidant activity. Once blood pressure values have been normalised as a result of the treatment, and with the consequent reduction in cellular oxidative stress, SOD and CAT anti-oxidant activity should also normalise, being less necessary, just as was observed in the results of this study. In effect, two months after the initiation of eprosartan administration, a reduction in SOD and CAT anti-oxidant enzyme activity was observed, and this value came close to that of the control group, which is thus described for the first time in the literature consulted. These results seem to confirm that leucocytes constitute an important target cell for eprosartan and that this drug normalises cellular oxidative stress by mechanisms different from the increase of SOD and CAT anti-oxidant activity.
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